Ardent Health, Inc. (ARDT) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Ardent Health, Inc. is a holding company operating 30 acute care hospitals across six states (Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas), along with rehabilitation and surgical hospitals. The company operates primarily through a joint venture model with academic medical centers and not-for-profit systems. As of June 30, 2025, the company had 143.1 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $1,645.3 million | $1,470.9 million | $3,142.5 million | $2,910.0 million |
| Net Income (GAAP) | $95.7 million | $67.0 million | $154.7 million | $112.8 million |
| Net Income Attributable to Ardent | $73.0 million | $42.8 million | $114.3 million | $69.8 million |
| Diluted EPS | $0.52 | $0.34 | $0.81 | $0.55 |
| Operating Cash Flow (YTD) | $92.7 million | $105.7 million | $92.7 million | $105.7 million |
| Cash and Equivalents | $540.6 million | $334.5 million | $540.6 million | $334.5 million |
| Total Debt (Carrying Value) | $1,109.7 million | $1,095.1 million | $1,109.7 million | $1,095.1 million |
| Adjusted EBITDA | $169.9 million | $122.3 million | $268.1 million | $218.1 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 11.9% in Q2 2025 and 8.0% YTD compared to the prior year. This was driven by a 10.2% increase in net patient service revenue per adjusted admission (Q2) and a 1.6% increase in adjusted admissions.
- Profitability: Net income attributable to Ardent Health, Inc. increased 70.6% in Q2 2025 ($73.0M vs $42.8M) and 63.8% YTD ($114.3M vs $69.8M). Operating margins improved as expenses decreased as a percentage of revenue.
- Insurance Recovery: The company recognized a $21.5 million gain from business interruption insurance proceeds related to a November 2023 cybersecurity incident during the six months ended June 30, 2025. No such proceeds were recognized in Q2 2025 alone.
- Interest Expense: Interest expense decreased to $14.7 million in Q2 2025 from $18.2 million in Q2 2024, attributed to a $100 million prepayment of the Term Loan B Facility in June 2024 and a subsequent repricing of the loan in September 2024.
- Acquisitions: On January 1, 2025, the company acquired 18 urgent care clinics in New Mexico and Oklahoma for $27.5 million.
Guidance, Outlook, and Risks
- Regulatory Impact (OBBBA): On July 4, 2025, Congress passed the "One Big Beautiful Bill Act" (OBBBA). The company notes this may negatively impact financial performance by reducing federal Medicaid expenditures, tightening eligibility requirements, and restricting provider assessments and directed payment programs. The company is currently analyzing the timing and magnitude of these impacts.
- Cybersecurity Litigation: A consolidated class action lawsuit regarding the 2023 cybersecurity incident was preliminarily approved for settlement in August 2025. The company states the settlement payments will not have a material impact on its financial position.
- Liquidity: As of June 30, 2025, available liquidity was $835.0 million, comprising $540.6 million in cash and $294.4 million in available capacity under the Asset-Based Lending (ABL) Credit Agreement. The net leverage ratio was 1.2x.
- Debt Structure: The company maintains a $325 million ABL facility (maturity June 2029) and a Term Loan B facility (approx. $774 million outstanding). Interest rate swaps cover approximately $400 million of variable rate debt exposure.
Key Investor Verification Points
- OBBBA Impact Analysis: Verify the company's specific modeling of revenue reductions due to the new Medicaid restrictions and provider assessment caps mandated by the OBBBA.
- Supplemental Program Revenue: Confirm the sustainability of the revenue growth driven by supplemental Medicaid programs, given the regulatory changes mentioned above.
- Cybersecurity Settlement Costs: Review the final settlement amount and any potential future litigation costs related to the 2023 incident, despite management's assertion of immateriality.
- Noncontrolling Interest (NCI) Earnings: Monitor the portion of net income attributable to NCI ($22.8M in Q2), which represents earnings from joint venture partners, to understand the true cash flow available to Ardent shareholders.
- Debt Covenants: Verify continued compliance with the Ventas Master Lease covenants (minimum portfolio coverage ratio of 2.2x) and credit facility covenants, particularly given the high lease-adjusted net leverage ratio of 2.7x.